Kiora Pharmaceuticals Inc.
KPRX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for KPRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · KPRX
Kiora Pharmaceuticals Inc. (KPRX) is a clinical-stage biopharmaceutical company focused on developing therapies for ophthalmic diseases, with lead candidates KIO-104 and KIO-301.
Key risk: Clinical trial failure risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 6 pipeline candidates · 3 clinical trials for Kiora Pharmaceuticals Inc..
Kiora Pharmaceuticals Inc. (KPRX) is a clinical-stage biopharmaceutical company focused on developing therapies for ophthalmic diseases, with lead candidates KIO-104 and KIO-301.
- Kiora Pharmaceuticals is developing KIO-104 for proliferative vitreoretinopathy (PVR) and KIO-301 for other ophthalmic indications [sec_mda · as of 2026-03-25].
- As of June 30, 2026, the company reported cash & equivalents of $7.1M, net income of -$2.1M, and shareholders' equity of $16.1M [sec].
- The company believes it has sufficient cash to fund planned operations into late 2028, but will need additional financing to complete product development [sec · filed 2026-05-18].
- Kiora has incurred significant net losses and expects to continue incurring increasing operating losses for the foreseeable future [sec_mda · as of 2026-03-25].
What works
- Kiora's KIO-104 program is considered ready for clinical trials in PVR, indicating progress toward a key milestone [sec · filed 2026-05-18].
- The company has extended its cash runway guidance from late 2027 (as of Dec 2025) to late 2028 (as of May 2026), suggesting improved financial management or reduced burn [sec_mda · as of 2026-03-25][sec · filed 2026-05-18].
- Kiora has a partnership with TOI for KIO-301 outside a specific territory, providing some non-dilutive funding and validation [sec_mda · as of 2025-11-07].
What to weigh
- Kiora has a history of significant net losses and expects expenses to increase with clinical development, raising going-concern risks [sec_mda · as of 2026-03-25].
- The company's future success depends heavily on KIO-104 and KIO-301; failure in clinical trials or regulatory approval would materially harm the business [sec_mda · as of 2026-03-25].
- Kiora will need to raise additional capital through debt, equity, or collaborations, and such financing may not be available on acceptable terms [sec · filed 2026-05-18].
- Cash and short-term investments have declined from $17.1M (Dec 2025) to $7.1M (Jun 2026), reflecting a high burn rate [sec_mda · as of 2026-03-25][sec].
From the filings
Quoted directly from source documents.
KIO-104 is ready for clinical trials in PVR.
“data package around KIO-104, we believe this program is ready for clinical trials in PVR.”
SEC filings · May 18, 2026
Cash runway extended to late 2028.
“we believe we will have sufficient cash to fund planned operations into late 2028.”
SEC filings · May 18, 2026
Company depends on KIO-104 and KIO-301 for future success.
“Our future success depends on our ability to retain key executives and to attract, retain, and motivate qualified personnel. • We depend heavily on the future success of KIO-104 and KIO-301.”
SEC MD&A · March 25, 2026
Net losses are significant and expected to increase.
“We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future.”
SEC MD&A · November 7, 2025
Risks & what to watch (4)›
Key risks
- Clinical trial failure risk — Failure of KIO-104 or KIO-301 in trials would materially harm the business [sec_mda · as of 2026-03-25].
- Capital needs and dilution — Additional financing required; may not be available on acceptable terms, leading to dilution or program delays [sec · filed 2026-05-18].
- Cash burn and runway — Cash declined from $17.1M (Dec 2025) to $7.1M (Jun 2026); runway depends on managing outflows [sec_mda · as of 2026-03-25][sec].
- Regulatory and commercial uncertainty — No approved products; regulatory approval and commercialization are uncertain and costly [sec_mda · as of 2026-03-25].
What to watch
- Initiation and progress of KIO-104 clinical trials for PVR [sec · filed 2026-05-18].
- Cash position and burn rate in upcoming quarterly filings to assess runway [sec].
- Any new financing, partnership, or licensing deals to extend capital [sec · filed 2026-05-18].
- Regulatory updates for KIO-301, including partnership progress with TOI [sec_mda · as of 2025-11-07].
Sources: SEC filings · SEC MD&A · Generated August 22, 2026 · How we verify sources →
Run Kiora Pharmaceuticals Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Kiora Pharmaceuticals Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
28.0 months
D/E 0.41 · 0% dilution
Lead: Phase 1/Phase 2
6 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
18
Total value held
$21.8M
| Holder | Shares | Value |
|---|---|---|
| alliancebernstein l.p. | 473,000 | $16.9M |
| wealth enhancement advisory services, llc | 106,690 | $3.8M |
| jane street group, llc | 13,440 | $475K |
| adar1 capital management, llc | 167,941 | $324K |
| citadel advisors llc | 49,533 | $96K |
| geode capital management, llc | 47,850 | $92K |
| vanguard capital management llc | 39,722 | $77K |
| xtx topco ltd | 14,719 | $28K |
| vanguard fiduciary trust co | 13,030 | $25K |
| two sigma securities, llc | 12,019 | $23K |
Showing top 10 of 18 institutional holders of Kiora Pharmaceuticals Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 0.7%
- Days to cover
- 0.0
- Shares short
- 30,793
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
KPRX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Kiora Pharmaceuticals Inc.?
Kiora Pharmaceuticals Inc. (KPRX) is a clinical-stage biopharmaceutical company focused on developing therapies for ophthalmic diseases, with lead candidates KIO-104 and KIO-301.
What is Kiora Pharmaceuticals Inc.'s lead drug candidate?
Kiora Pharmaceuticals Inc.'s most advanced tracked candidate is kio-101 (Phase 2) for Ocular manifestation of autoimmune diseases (OPRA+).
Who is the CEO of Kiora Pharmaceuticals Inc.?
Dr. Brian M. Strem Ph.D. is the chief executive officer of Kiora Pharmaceuticals Inc. (KPRX).
Where is Kiora Pharmaceuticals Inc. headquartered?
Kiora Pharmaceuticals Inc. (KPRX) is headquartered in Encinitas, CA, United States.
What therapeutic areas does Kiora Pharmaceuticals Inc. focus on?
Kiora Pharmaceuticals Inc. develops therapies across Oncology, Immunology, Ophthalmology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.